X
Xavier Garcia-del-Muro
Researcher at University of Barcelona
Publications - 11
Citations - 2948
Xavier Garcia-del-Muro is an academic researcher from University of Barcelona. The author has contributed to research in topics: Sunitinib & Medicine. The author has an hindex of 6, co-authored 8 publications receiving 2427 citations.
Papers
More filters
Journal ArticleDOI
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Roberto Pili,Georg A. Bjarnason,Xavier Garcia-del-Muro,Jeffrey A. Sosman,Ewa Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin +18 more
TL;DR: Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
Journal ArticleDOI
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Matthew D. Galsky,Jose Angel Arranz Arija,Aristotelis Bamias,Ian D. Davis,Maria De Santis,Eiji Kikuchi,Xavier Garcia-del-Muro,Ugo De Giorgi,Marina Mencinger,Kouji Izumi,Stefano Panni,Mahmut Gumus,Mustafa Ozguroglu,Arash Rezazadeh Kalebasty,Se Hoon Park,Boris Alekseev,Fabio A.B. Schutz,Jian Ri Li,Dingwei Ye,Nicholas J. Vogelzang,Sandrine Bernhard,Darren Tayama,Sanjeev Mariathasan,Almut Mecke,Ann Christine Thastrom,Enrique Grande +25 more
TL;DR: The results of IMvigor130 support the use of atezolizumab plus platinum-based chemotherapy as a potential first-line treatment option for metastatic urothelial carcinoma and the safety profile of the combination was consistent with that observed with the individual agents.
Journal ArticleDOI
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
Xavier Garcia-del-Muro,Antonio Lopez-Pousa,Joan Maurel,Javier Martín,Javier Martinez-Trufero,Antonio Casado,Auxiliadora Gómez-España,Joaquin Fra,Josefina Cruz,Andres Poveda,Andrés Meana,Carlos Pericay,Ricardo Cubedo,Jordi Rubió,Ana de Juan,Nuria Lainez,Juan Antonio Carrasco,Raquel Andrés,J. Buesa +18 more
TL;DR: The combination of gemcitabine and DTIC is active and well tolerated in patients with STS, providing in this phase II randomized trial superior progression-free survival and overall survival than DTIC alone.
Journal ArticleDOI
Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study
Xavier Garcia-del-Muro,Pablo Maroto,Josep Guma,Javier Sastre,Marta Lopez Brea,Jose Angel Arranz,Nuria Lainez,Diego Soto de Prado,Jorge Aparicio,J.M. Piulats,X. Perez,J. R. Germa-Lluch +11 more
TL;DR: Chemotherapy is a highly effective and well-tolerated treatment for patients with stage IIA or IIB seminoma and represents an available alternative that could avoid some of the serious late effects associated with radiotherapy.
Journal ArticleDOI
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Silke Gillessen,Silke Gillessen,Nicolas Sauvé,Laurence Collette,Gedske Daugaard,Ronald de Wit,Costantine Albany,Alexey Tryakin,Karim Fizazi,Olof Ståhl,Jourik A. Gietema,Ugo De Giorgi,Fay H. Cafferty,Aaron R. Hansen,Torgrim Tandstad,Robert Huddart,Andrea Necchi,Christopher Sweeney,Xavier Garcia-del-Muro,Daniel Y.C. Heng,Anja Lorch,Anja Lorch,Michal Chovanec,Eric Winquist,Peter Grimison,Darren R. Feldman,Darren R. Feldman,Angelika Terbuch,Marcus Hentrich,Carsten Bokemeyer,Helene F. S. Negaard,Christian D. Fankhauser,Jonathan Shamash,David J. Vaughn,Cora N. Sternberg,Axel Heidenreich,Jörg Beyer +36 more
TL;DR: The International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990.